Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
7 results loaded, newest first. End of these results.
On Monday, Inventiva (NASDAQ: IVA ) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Inventiva reported a strong financial position w
Pfizer (NYSE: PFE ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Full Transcript OPERATOR Good day everyone and wel
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary HUTCHMED (
BeiGene (NASDAQ: ONC ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary BeiGene reported strong Q2 2026 financial results with $1.7 billion in t
Takeda Pharmaceutical Co (NYSE: TAK ) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. Access the full call at Summary Takeda Pharmace
On Wednesday, Kura Oncology (NASDAQ: KURA ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Kura Oncology reported $9.1 million in n
The therapy’s autoimmune-disease data point to strong efficacy and a differentiated safety profile, with pivotal results and a BLA filing expected next year.